The main risk is a broken proof chain: better fidelity, larger systems, and sovereign interest still have to convert into accepted installations, recurring capacity revenue, and defendable economics before valuation, competition, and future
dilution catch up. Rigetti has real assets and real technical progress, but the stock remains far more sensitive to commercial validation than to another roadmap promise.